{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:05:27Z","timestamp":1791828327083,"version":"4.3.4"},"reference-count":137,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","mayoclinicproceedings.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.mayocp.2016.09.010","type":"journal-article","created":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T11:15:35Z","timestamp":1477998935000},"page":"1645-1666","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":210,"title":["Adult Acute Lymphoblastic Leukemia"],"prefix":"10.1016","volume":"91","author":[{"given":"Shilpa","family":"Paul","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias J.","family":"Jabbour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"26","key":"10.1016\/j.mayocp.2016.09.010_bib1","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1056\/NEJMoa0900386","article-title":"Treating childhood acute lymphoblastic leukemia without cranial irradiation","volume":"360","author":"Pui","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.mayocp.2016.09.010_bib2","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1200\/JCO.2000.18.3.547","article-title":"Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia","volume":"18","author":"Kantarjian","year":"2000","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.mayocp.2016.09.010_bib3","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/j.1365-2141.2012.09095.x","article-title":"Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII\/ECOG2993 trial","volume":"157","author":"Sive","year":"2012","journal-title":"Br J Haematol"},{"issue":"15","key":"10.1016\/j.mayocp.2016.09.010_bib4","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1002\/cncr.29383","article-title":"New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia","volume":"121","author":"Jabbour","year":"2015","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.mayocp.2016.09.010_bib5","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3322\/canjclin.54.1.8","article-title":"Cancer Statistics, 2004","volume":"54","author":"Jemal","year":"2004","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.mayocp.2016.09.010_bib6","unstructured":"American\u00a0Cancer Society. Cancer Facts & Figures\u00a02016. American\u00a0Cancer Society website. www.cancer.org\/research\/cancerfactsstatistics\/cancerfactsfigures2016. Accessed December 20,\u00a02016."},{"issue":"1","key":"10.1016\/j.mayocp.2016.09.010_bib7","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3322\/caac.21254","article-title":"Cancer statistics, 2015","volume":"65","author":"Siegel","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.mayocp.2016.09.010_bib8","unstructured":"National Comprehensive Cancer Network. Acute lymphoid leukemia (version 2.2015). http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/all.pdf. Accessed December 20,\u00a02015."},{"key":"10.1016\/j.mayocp.2016.09.010_bib9","unstructured":"National Cancer Institute. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/all.pdf. Accessed October 7, 2016."},{"issue":"7","key":"10.1016\/j.mayocp.2016.09.010_bib10","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S1470-2045(00)00435-6","article-title":"Pattern of malignant disorders in individuals with Down's syndrome","volume":"2","author":"Hasle","year":"2001","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.mayocp.2016.09.010_bib11","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1111\/j.1365-2141.2006.06337.x","article-title":"Down syndrome and acute lymphoblastic leukaemia","volume":"135","author":"Whitlock","year":"2006","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.mayocp.2016.09.010_bib12","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3109\/08880019209006400","article-title":"Acute lymphoblastic leukemia and Klinefelter's syndrome","volume":"9","author":"Shaw","year":"1992","journal-title":"Pediatr Hematol Oncol"},{"issue":"2","key":"10.1016\/j.mayocp.2016.09.010_bib13","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3109\/08880019409141662","article-title":"Acute lymphoblastic leukemia associated with Klinefelter syndrome","volume":"11","author":"Gurgey","year":"1994","journal-title":"Pediatr Hematol Oncol"},{"issue":"1","key":"10.1016\/j.mayocp.2016.09.010_bib14","first-page":"45","article-title":"Acute lymphoblastic leukemia in Fanconi's anemia","volume":"47","author":"Yetgin","year":"1994","journal-title":"Am J Hematol"},{"issue":"3-4","key":"10.1016\/j.mayocp.2016.09.010_bib15","first-page":"179","article-title":"Bloom's syndrome: the German experience","volume":"34","author":"Passarge","year":"1991","journal-title":"Ann Genet"},{"issue":"2","key":"10.1016\/j.mayocp.2016.09.010_bib16","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1182\/blood.V87.2.423.bloodjournal872423","article-title":"Leukemia and lymphoma in ataxia telangiectasia","volume":"87","author":"Taylor","year":"1996","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.mayocp.2016.09.010_bib17","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1046\/j.1365-2141.2002.03372.x","article-title":"Epstein-Barr virus-associated T-cell acute lymphoblastic leukaemia","volume":"117","author":"Sakajiri","year":"2002","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.mayocp.2016.09.010_bib18","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1093\/oxfordjournals.annonc.a058876","article-title":"Heterogeneity of acute lymphoblastic leukemia in HIV-seropositive patients","volume":"5","author":"G\u00e9rini\u00e8re","year":"1994","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.mayocp.2016.09.010_bib19","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.4065\/80.11.1517","article-title":"Adult acute lymphoblastic leukemia","volume":"80","author":"Jabbour","year":"2005","journal-title":"Mayo Clin Proc"},{"issue":"5","key":"10.1016\/j.mayocp.2016.09.010_bib20","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1002\/cncr.24862","article-title":"Adult acute lymphoblastic leukemia: concepts and strategies","volume":"116","author":"Faderl","year":"2010","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.mayocp.2016.09.010_bib21","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1136\/jcp.39.9.998","article-title":"French American British (FAB) morphological classification of childhood lymphoblastic leukaemia and its clinical importance","volume":"39","author":"Lilleyman","year":"1986","journal-title":"J\u00a0Clin Pathol"},{"issue":"10","key":"10.1016\/j.mayocp.2016.09.010_bib22","first-page":"1783","article-title":"Proposals for the immunological classification of acute leukemias: European Group for the Immunological Characterization of Leukemias (EGIL)","volume":"9","author":"Bene","year":"1995","journal-title":"Leukemia"},{"key":"10.1016\/j.mayocp.2016.09.010_bib23","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","first-page":"168","article-title":"B\u00a0lymphoblastic leukaemia\/lymphoma, not otherwise specified","author":"Borowitz","year":"2008"},{"key":"10.1016\/j.mayocp.2016.09.010_bib24","series-title":"WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues","first-page":"176","article-title":"T\u00a0lymphoblastic leukemia\/lymphoma","author":"Borowitz","year":"2008"},{"issue":"1-2","key":"10.1016\/j.mayocp.2016.09.010_bib25","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.cbi.2009.10.009","article-title":"The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues: an overview with emphasis on the myeloid neoplasms","volume":"184","author":"Vardiman","year":"2010","journal-title":"Chem Biol Interact"},{"issue":"20","key":"10.1016\/j.mayocp.2016.09.010_bib26","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision of the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.mayocp.2016.09.010_bib27","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMra023001","article-title":"Acute lymphoblastic leukemia","volume":"350","author":"Pui","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"25","key":"10.1016\/j.mayocp.2016.09.010_bib28","doi-asserted-by":"crossref","first-page":"6330","DOI":"10.1182\/blood-2008-04-151860","article-title":"Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia","volume":"113","author":"Thomas","year":"2009","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.mayocp.2016.09.010_bib29","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S1470-2045(08)70314-0","article-title":"Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia","volume":"10","author":"Coustan-Smith","year":"2009","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.mayocp.2016.09.010_bib30","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1038\/sj.leu.2404302","article-title":"Cytogenetics and molecular genetics of T-cell acute lymphoblastic leukemia: from thymocyte to lymphoblast","volume":"20","author":"Graux","year":"2006","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.mayocp.2016.09.010_bib31","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1182\/blood-2009-07-232124","article-title":"A\u00a0population-based cytogenetic study of adults with acute lymphoblastic leukemia","volume":"115","author":"Moorman","year":"2010","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.mayocp.2016.09.010_bib32","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1182\/blood-2006-10-051912","volume":"109","author":"Moorman","year":"2007","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.mayocp.2016.09.010_bib33","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1182\/blood-2007-10-116186","article-title":"Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 study","volume":"111","author":"Pullarkat","year":"2008","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.mayocp.2016.09.010_bib34","doi-asserted-by":"crossref","first-page":"3995","DOI":"10.1182\/blood.V91.11.3995","article-title":"Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia","volume":"91","author":"Faderl","year":"1998","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.mayocp.2016.09.010_bib35","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1182\/blood-2015-02-580043","article-title":"Redefining ALL classification: toward detecting high-risk ALL and implementing precision medicine","volume":"125","author":"Hunger","year":"2015","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.mayocp.2016.09.010_bib36","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/nrclinonc.2015.38","article-title":"Genomics in acute lymphoblastic leukaemia: insights and treatment implications","volume":"12","author":"Roberts","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"issue":"11","key":"10.1016\/j.mayocp.2016.09.010_bib37","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa1403088","article-title":"Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia","volume":"371","author":"Roberts","year":"2014","journal-title":"N\u00a0Eng J Med"},{"issue":"2","key":"10.1016\/j.mayocp.2016.09.010_bib38","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S1470-2045(08)70339-5","article-title":"A\u00a0subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study","volume":"10","author":"Den Boer","year":"2009","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.mayocp.2016.09.010_bib39","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1056\/NEJMoa0808253","article-title":"Children's Oncology Group. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia","volume":"360","author":"Mullighan","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.mayocp.2016.09.010_bib40","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1038\/ng.469","article-title":"Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia","volume":"41","author":"Mullighan","year":"2009","journal-title":"Nat Genet"},{"issue":"13","key":"10.1016\/j.mayocp.2016.09.010_bib41","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1182\/blood-2009-03-208397","article-title":"Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia","volume":"114","author":"Russell","year":"2009","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.mayocp.2016.09.010_bib42","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1182\/blood-2009-08-235408","article-title":"Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group","volume":"115","author":"Hertzberg","year":"2010","journal-title":"Blood"},{"issue":"27","key":"10.1016\/j.mayocp.2016.09.010_bib43","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1200\/JCO.2014.55.4105","article-title":"Outcomes of children with BCR-ABL1\u2013like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease","volume":"32","author":"Roberts","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.mayocp.2016.09.010_bib44","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/mpo.2950190411","article-title":"Lower incidence of meningeal leukemia when prednisone is replaced by dexamethasone in the treatment of acute lymphocytic leukemia","volume":"19","author":"Jones","year":"1991","journal-title":"Med Pediatr Oncol"},{"issue":"8","key":"10.1016\/j.mayocp.2016.09.010_bib45","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1002\/(SICI)1097-0142(20000415)88:8<1964::AID-CNCR27>3.0.CO;2-1","article-title":"Substituting dexamethasone for prednisone complicates remission induction in children with acute lymphoblastic leukemia","volume":"88","author":"Hurwitz","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.mayocp.2016.09.010_bib46","doi-asserted-by":"crossref","first-page":"3900","DOI":"10.1182\/blood.V122.21.3900.3900","article-title":"Feasibility of pegylated-asparaginase (PEG-ASP) during induction in adults with acute lymphoblastic leukameia (ALL): results from UK phase 3 multicentre trial UKALL14","volume":"122","author":"Patel","year":"2013","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.mayocp.2016.09.010_bib47","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1002\/cncr.20668","article-title":"Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia","volume":"101","author":"Kantarjian","year":"2004","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.mayocp.2016.09.010_bib48","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1038\/sj.leu.2400861","article-title":"The hyper-CVAD regimen improves outcome in relapsed acute lymphoblastic leukemia","volume":"11","author":"Koller","year":"1997","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.mayocp.2016.09.010_bib49","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1002\/ajh.24419","article-title":"Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-Munster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen","volume":"91","author":"Rytting","year":"2016","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.mayocp.2016.09.010_bib50","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1200\/JCO.2010.30.1382","article-title":"Modern therapy of acute lymphoblastic leukemia","volume":"29","author":"Bassan","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"9018","key":"10.1016\/j.mayocp.2016.09.010_bib51","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/S0140-6736(96)91615-3","article-title":"Duration and intensity of maintenance chemotherapy in acute lymphoblastic leukaemia: overview of 42 trials involving 12 000 randomised children","volume":"347","year":"1996","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.mayocp.2016.09.010_bib52","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.critrevonc.2011.01.014","article-title":"Treatment of acute lymphoblastic leukemia in adults","volume":"81","author":"Narayanan","year":"2012","journal-title":"Crit Rev Oncol Hematol"},{"issue":"2","key":"10.1016\/j.mayocp.2016.09.010_bib53","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1182\/blood.V87.2.495.bloodjournal872495","article-title":"Improved outcome in adult B-cell acute lymphoblastic leukemia","volume":"87","author":"Hoelzer","year":"1996","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.mayocp.2016.09.010_bib54","doi-asserted-by":"crossref","first-page":"3761","DOI":"10.1200\/JCO.1998.16.12.3761","article-title":"Secondary brain tumors in children treated for acute lymphoblastic leukemia at St Jude Children\u2019s Research Hospital","volume":"16","author":"Walter","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.mayocp.2016.09.010_bib55","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1056\/NEJM199307293290504","article-title":"Low leukocyte counts with blast cells in cerebrospinal fluid of children with newly diagnosed acute lymphoblastic leukemia","volume":"329","author":"Mahmoud","year":"1993","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.mayocp.2016.09.010_bib56","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.hoc.2014.08.008","article-title":"Allogeneic hematopoietic cell transplantation in adult patients with acute lymphoblastic leukemia","volume":"28","author":"Marks","year":"2014","journal-title":"Hematol Oncol Clin North Am"},{"issue":"18","key":"10.1016\/j.mayocp.2016.09.010_bib57","doi-asserted-by":"crossref","first-page":"4153","DOI":"10.1182\/blood-2008-11-185132","article-title":"Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)","volume":"113","author":"Bassan","year":"2009","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.mayocp.2016.09.010_bib58","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1182\/blood-2014-09-599894","article-title":"Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia","volume":"125","author":"Dh\u00e9din","year":"2015","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.mayocp.2016.09.010_bib59","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1182\/blood-2011-09-377713","article-title":"Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies","volume":"120","author":"G\u00f6kbuget","year":"2012","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.mayocp.2016.09.010_bib60","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1200\/JCO.2013.52.2425","volume":"32","author":"Ribera","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.mayocp.2016.09.010_bib61","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1053\/j.seminoncol.2011.11.009","article-title":"Acute lymphoblastic leukemia: monitoring minimal residual disease as a therapeutic principle","volume":"39","author":"Br\u00fcggemann","year":"2012","journal-title":"Semin Oncol"},{"issue":"3","key":"10.1016\/j.mayocp.2016.09.010_bib62","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1182\/blood-2006-07-037093","article-title":"Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06\/99 and 07\/03 trials","volume":"109","author":"Raff","year":"2007","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.mayocp.2016.09.010_bib63","doi-asserted-by":"crossref","first-page":"5477","DOI":"10.1182\/blood-2008-01-132837","article-title":"Children's Oncology Group. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study","volume":"111","author":"Borowitz","year":"2008","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.mayocp.2016.09.010_bib64","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/bjh.13834","article-title":"Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia","volume":"172","author":"Ravandi","year":"2016","journal-title":"Br J Hematol"},{"issue":"7","key":"10.1016\/j.mayocp.2016.09.010_bib65","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1182\/blood-2008-06-164863","article-title":"Improvement in survival in younger patients with acute lymphoblastic leukemia from the 1980s to the early 21st century","volume":"113","author":"Pulte","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.mayocp.2016.09.010_bib66","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1182\/blood.V124.21.796.796","article-title":"Favorable outcomes for older adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL): early results of U.S. intergroup trial C10403","volume":"124","author":"Stock","year":"2014","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.mayocp.2016.09.010_bib67","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1200\/JCO.2008.18.6916","article-title":"Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study","volume":"27","author":"Huguet","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"21","key":"10.1016\/j.mayocp.2016.09.010_bib68","doi-asserted-by":"crossref","first-page":"3714","DOI":"10.1182\/blood.V124.21.3714.3714","article-title":"Intensified chemotherapy for older patients with acute lymphoblastic leukemia (ALL): a phase II study from the Dana Farber Cancer Institute (DFCI) ALL consortium","volume":"124","author":"Fathi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.mayocp.2016.09.010_bib69","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/leu.2014.229","article-title":"A\u00a0multicenter phase II study using a dose intensified pegylated-asparaginase pediatric regimen in adults with untreated acute lymphoblastic leukemia: a DFCI ALL consortium trial","volume":"29","author":"DeAngelo","year":"2015","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.mayocp.2016.09.010_bib70","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1182\/blood-2012-07-379016","article-title":"How I treat older patients with ALL","volume":"122","author":"G\u00f6kbuget","year":"2013","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.mayocp.2016.09.010_bib71","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1002\/cncr.23819","article-title":"Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia","volume":"113","author":"O'Brien","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.mayocp.2016.09.010_bib72","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1182\/blood.V120.21.1493.1493","volume":"120","author":"Goekbuget","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.mayocp.2016.09.010_bib73","first-page":"83","article-title":"Inotuzumab ozogamicin (INO) in combination with low-intensity chemotherapy (mini-hyper-CD) as frontline therapy for older patients (\u226560 years) with acute lymphoblastic leukemia (ALL)","volume":"124","author":"Jabbour","year":"2014","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.mayocp.2016.09.010_bib74","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1200\/JCO.2001.19.8.2165","article-title":"Rituximab dose-escalation trial in chronic lymphocytic leukemia","volume":"19","author":"O\u2019Brien","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.mayocp.2016.09.010_bib75","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.mayocp.2016.09.010_bib76","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/cncr.21776","article-title":"Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia","volume":"106","author":"Thomas","year":"2006","journal-title":"Cancer"},{"issue":"26","key":"10.1016\/j.mayocp.2016.09.010_bib77","doi-asserted-by":"crossref","first-page":"3870","DOI":"10.1182\/blood-2014-03-563627","article-title":"Improved outcome of adult Burkitt lymphoma\/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial","volume":"124","author":"Hoelzer","year":"2014","journal-title":"Blood"},{"issue":"10036","key":"10.1016\/j.mayocp.2016.09.010_bib78","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1016\/S0140-6736(15)01317-3","article-title":"Rituximab and dose-dense chemotherapy for adults with Burkitt\u2019s lymphoma: a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Ribrag","year":"2016","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.mayocp.2016.09.010_bib79","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1056\/NEJMoa1308392","article-title":"Low-intensity therapy in adults with Burkitt\u2019s lymphoma","volume":"369","author":"Dunleavy","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"10.1016\/j.mayocp.2016.09.010_bib80","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1200\/JCO.2009.26.9456","article-title":"Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcomes in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia","volume":"28","author":"Thomas","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"21","key":"10.1016\/j.mayocp.2016.09.010_bib81","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1182\/blood.V116.21.170.170","article-title":"Immunochemotherapy with rituximab improves molecular CR rate and outcome in CD20+ B-lineage standard and high risk patients: results of 263 CD20+ patients studied prospectively in GMALL study 07\/2003","volume":"116","author":"Hoelzer","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.mayocp.2016.09.010_bib82","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.blre.2011.08.001","article-title":"Chemoimmunotherapy in acute lymphoblastic leukemia","volume":"26","author":"Hoelzer","year":"2012","journal-title":"Blood Rev"},{"issue":"23","key":"10.1016\/j.mayocp.2016.09.010_bib83","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood.V126.23.1.1","article-title":"Addition of rituximab improves the outcome of adult patients with CD20-positive, Ph-negative, B-cell precursor acute lymphoblastic leukemia (BCP-ALL): results of the randomized GRAALL-R 2005 study","volume":"126","author":"Maury","year":"2015","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.mayocp.2016.09.010_bib84","doi-asserted-by":"crossref","first-page":"5126","DOI":"10.1182\/blood-2011-04-348656","article-title":"Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study","volume":"118","author":"Wierda","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.mayocp.2016.09.010_bib85","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1182\/blood.V126.23.1295.1295","article-title":"Phase II study of the frontline hyper-cvad in combination with ofatumumab for adult patients (pts) with cd-20 positive acute lymphoblastic leukemia (ALL)","volume":"126","author":"Sasaki","year":"2015","journal-title":"Blood"},{"issue":"3-4","key":"10.1016\/j.mayocp.2016.09.010_bib86","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3109\/10428190009148847","article-title":"Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia","volume":"36","author":"Faderl","year":"2000","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1016\/j.mayocp.2016.09.010_bib87","first-page":"119","article-title":"Philadelphia chromosome positive adult acute lymphoblastic leukemia: characteristics, prognostic factors and treatment outcome","volume":"40","author":"Thomas","year":"1998","journal-title":"Hematol Cell Ther"},{"issue":"7","key":"10.1016\/j.mayocp.2016.09.010_bib88","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1182\/blood-2002-03-0704","article-title":"Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia\u2014results of the prospective multicenter LALA-94 trial","volume":"100","author":"Dombret","year":"2002","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.mayocp.2016.09.010_bib89","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.bbmt.2012.08.021","article-title":"Long-term follow-up of the imatinib GRAAPH-2003 study in newly diagnosed patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: a GRAALL study","volume":"19","author":"Tanguy-Schmidt","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.mayocp.2016.09.010_bib90","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1182\/blood-2013-09-529008","article-title":"UKALLXII\/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia","volume":"123","author":"Fielding","year":"2014","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.mayocp.2016.09.010_bib91","doi-asserted-by":"crossref","first-page":"4396","DOI":"10.1182\/blood-2003-08-2958","article-title":"Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate","volume":"103","author":"Thomas","year":"2004","journal-title":"Blood"},{"issue":"15, suppl","key":"10.1016\/j.mayocp.2016.09.010_bib92","doi-asserted-by":"crossref","first-page":"6506","DOI":"10.1200\/jco.2010.28.15_suppl.6506","article-title":"Long-term outcome after hyper-CVAD and imatinib (IM) for de novo or minimally treated Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-ALL)","volume":"28","author":"Thomas","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"31","key":"10.1016\/j.mayocp.2016.09.010_bib93","doi-asserted-by":"crossref","first-page":"5175","DOI":"10.1200\/JCO.2008.21.2514","article-title":"Improved early event-free survival with imatinib in Philadelphia chromosome-positivie acute lymphoblastic leukemia: a Children\u2019s Oncology Group study","volume":"27","author":"Schultz","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"24","key":"10.1016\/j.mayocp.2016.09.010_bib94","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.1182\/blood-2015-02-627935","article-title":"Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia","volume":"125","author":"Chalandon","year":"2015","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.mayocp.2016.09.010_bib95","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1002\/cncr.23666","article-title":"Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors","volume":"113","author":"Jones","year":"2008","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.mayocp.2016.09.010_bib96","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1080\/10428190310001593184","article-title":"Isolated central nervous system relapse in lymphoid blast crisis chronic myeloid leukemia and acute lymphoblastic leukemia in patients on imatinib therapy","volume":"45","author":"Bujassoum","year":"2004","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"10.1016\/j.mayocp.2016.09.010_bib97","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/ng1343","article-title":"Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia","volume":"36","author":"Hu","year":"2004","journal-title":"Nat Genet"},{"issue":"4","key":"10.1016\/j.mayocp.2016.09.010_bib98","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1182\/blood-2008-02-140665","article-title":"Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia","volume":"112","author":"Porkka","year":"2008","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.mayocp.2016.09.010_bib99","doi-asserted-by":"crossref","first-page":"4158","DOI":"10.1002\/cncr.29646","article-title":"Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"121","author":"Ravandi","year":"2015","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.mayocp.2016.09.010_bib100","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1182\/blood.V126.23.796.796","article-title":"Multi-center US intergroup of intensive chemotherapy plus dasatinib followed by allogeneic stem cell transplant in patients with Philadelphia chromosome positivie acute lymphoblastic leukemia younger than 60","volume":"126","author":"Ravandi","year":"2015","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.mayocp.2016.09.010_bib101","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1182\/blood-2016-02-700153","article-title":"Dasatinib and low-intensity chemotherapy in elderly patiens with Philadelphia chromosome-positive ALL","volume":"128","author":"Rousselot","year":"2016","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.mayocp.2016.09.010_bib102","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1182\/blood.V126.23.81.81","article-title":"Multicenter total therapy Gimema LAL 1509 protocol for de novo adult Ph+ acute lymphoblastic leukemia (ALL) patients: updated results and refined genetic-based prognostic stratification","volume":"126","author":"Chiaretti","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.mayocp.2016.09.010_bib103","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1182\/blood.V124.21.798.798","article-title":"Nilotinib (Tasigna\u00ae) and chemotehrapy for first-line treatment in elderly patients with de novo Philadelphia chromosome\/BCR-ABL1 positive acute lymphoblastic leukemia (ALL): a trial of the European Working Group for Adult ALL (EWALL-PH-02)","volume":"124","author":"Ottmann","year":"2014","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.mayocp.2016.09.010_bib104","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance","volume":"16","author":"O\u2019Hare","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.mayocp.2016.09.010_bib105","series-title":"Iclusig (ponatinib) [prescribing information]","year":"2015"},{"key":"10.1016\/j.mayocp.2016.09.010_bib106","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1182\/blood.V124.21.3135.3135","article-title":"Long-term follow-up of ponatinib efficacy and safety in the phase 2 PACE trial","volume":"124","author":"Cortes","year":"2014","journal-title":"Blood"},{"issue":"15, suppl","key":"10.1016\/j.mayocp.2016.09.010_bib107","doi-asserted-by":"crossref","first-page":"7036","DOI":"10.1200\/JCO.2016.34.15_suppl.7036","article-title":"Updated results from phase II study of combination of hyper-CVAD (HCVAD) with ponatinib in frontline therapy of patients (pts) with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL)","volume":"34","author":"Sasaki","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"15, suppl","key":"10.1016\/j.mayocp.2016.09.010_bib108","doi-asserted-by":"crossref","first-page":"7025","DOI":"10.1200\/JCO.2016.34.15_suppl.7025","article-title":"Propensity score analysis: frontline therapy with hyper-CVAD (HCVAD)\u00a0+ ponatinib vs. HCVAD\u00a0+ dasatinib in patients (pts) with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL)","volume":"34","author":"Sasaki","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.mayocp.2016.09.010_bib109","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1182\/blood-2012-11-466482","article-title":"Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy","volume":"122","author":"Ravandi","year":"2013","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.mayocp.2016.09.010_bib110","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1182\/blood-2016-03-707562","article-title":"Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"128","author":"Short","year":"2016","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.mayocp.2016.09.010_bib111","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1182\/blood-2005-11-4386","article-title":"Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)","volume":"108","author":"Wassmann","year":"2006","journal-title":"Blood"},{"issue":"7380","key":"10.1016\/j.mayocp.2016.09.010_bib112","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/nature10725","article-title":"The genetic basis of early T-cell precursor acute lymphoblastic leukaemia","volume":"481","author":"Zhang","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.mayocp.2016.09.010_bib113","series-title":"Arranon (nelarabine) package insert","year":"2011"},{"issue":"5","key":"10.1016\/j.mayocp.2016.09.010_bib114","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.hoc.2009.07.008","article-title":"Nelarabine for the treatment of patients with relapsed or refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma","volume":"23","author":"DeAngelo","year":"2009","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.mayocp.2016.09.010_bib115","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1182\/blood-2015-08-661702","article-title":"Early T-cell precursor acute lymphoblastic leukemia\/lymphoma (ETP-ALL\/LBL) in adolescents and adults: a high-risk subtype","volume":"127","author":"Jain","year":"2016","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.mayocp.2016.09.010_bib116","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1038\/sj.leu.2404824","article-title":"Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial","volume":"21","author":"Tavernier","year":"2007","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.mayocp.2016.09.010_bib117","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1182\/blood-2011-12-399287","article-title":"Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation","volume":"120","author":"G\u00f6kbuget","year":"2012","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.mayocp.2016.09.010_bib118","doi-asserted-by":"crossref","first-page":"5568","DOI":"10.1002\/cncr.25354","article-title":"Defining the\u00a0course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration","volume":"116","author":"Kantarjian","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.mayocp.2016.09.010_bib119","series-title":"Blincyto (blinatumomab) [prescribing information]","year":"2014"},{"issue":"3","key":"10.1016\/j.mayocp.2016.09.010_bib120","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.pharmthera.2012.07.013","article-title":"Blinatumomab: a historical perspective","volume":"136","author":"Nagorsen","year":"2012","journal-title":"Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.mayocp.2016.09.010_bib121","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s40265-015-0356-3","article-title":"Blinatumomab: first global approval","volume":"75","author":"Sanford","year":"2015","journal-title":"Drugs"},{"issue":"26","key":"10.1016\/j.mayocp.2016.09.010_bib122","doi-asserted-by":"crossref","first-page":"5185","DOI":"10.1182\/blood-2012-07-441030","article-title":"Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL","volume":"120","author":"Topp","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.mayocp.2016.09.010_bib123","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1182\/blood.V126.23.680.680","article-title":"Long-term outcomes after blinatumomab treatment: follow-up of a phase 2 study in patients (Pts) with minimal residual disease (MRD) positive B-cell precursor acute lymphoblastic leukemia (ALL)","volume":"126","author":"G\u00f6kbuget","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.mayocp.2016.09.010_bib124","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multi-centre, single-arm, phase 2 study","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.mayocp.2016.09.010_bib125","unstructured":"Topp MS, Stein A, G\u00f6kbuget N, et\u00a0al. Blinatumomab improved overall survival in patients with relapsed or refractory Philadelphia negative B-cell precursor acute lymphoblastic leukemia in a randomized, open-label phase 3 study (TOWER) [abstract S149]. European Hematology Association Learning Center website. http:\/\/learningcenter.ehaweb.org\/eha\/2016\/21st\/135182\/max.topp.blinatumomab.improved.overall.survival.in.patients.with.relapsed.or.html?f=m3s168109e968. Accessed September 21, 2016."},{"key":"10.1016\/j.mayocp.2016.09.010_bib126","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1182\/blood.V126.23.679.679","volume":"126","author":"Martinelli","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.mayocp.2016.09.010_bib127","doi-asserted-by":"crossref","first-page":"6500","DOI":"10.1200\/jco.2012.30.15_suppl.6500","article-title":"Effect of anti-CD19 bite blinatumomab on complete remission rate and overall survival in adult patients with relapsed\/refractory B-precursor ALL","volume":"30","author":"Topp","year":"2012","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.mayocp.2016.09.010_bib128","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1200\/JCO.2009.25.1900","article-title":"Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study","volume":"28","author":"Advani","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.mayocp.2016.09.010_bib129","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S1470-2045(11)70386-2","article-title":"Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study","volume":"13","author":"Kantarjian","year":"2012","journal-title":"Lancet Oncol"},{"issue":"15","key":"10.1016\/j.mayocp.2016.09.010_bib130","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1002\/cncr.28136","article-title":"Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia","volume":"119","author":"Kantarjian","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.mayocp.2016.09.010_bib131","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1182\/blood.V124.21.2255.2255","article-title":"A\u00a0phase II study of weekly inotuzumab ozogamicin (InO) in adult patients with CD22-positive acute lymphoblastic leukemia (ALL) in second or later salvage","volume":"124","author":"Advani","year":"2014","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.mayocp.2016.09.010_bib132","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"23","key":"10.1016\/j.mayocp.2016.09.010_bib133","doi-asserted-by":"crossref","first-page":"3721","DOI":"10.1182\/blood.V126.23.3721.3721","article-title":"Salvage chemotherapy with inotuzumab ozogamicin (INO) combined with mini-hyper-CVD for adult patients with relapsed\/refractory (R\/R) acute lymphoblastic leukemia (ALL)","volume":"126","author":"Sasaki","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.mayocp.2016.09.010_bib134","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrclinonc.2015.187","article-title":"Novel immunotherapies in lymphoid malignancies","volume":"13","author":"Batlevi","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"issue":"16","key":"10.1016\/j.mayocp.2016.09.010_bib135","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"23","key":"10.1016\/j.mayocp.2016.09.010_bib136","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1182\/blood.V126.23.682.682","article-title":"Implications of minimal residual disease negative complete remission (MRD-CR) and allogenic stem cell transplant on safety and clinical outcome of CD19-targeted 19-28z CAR modified T cells in adult patients with relapsed, refractroy B-cell ALL","volume":"126","author":"Park","year":"2015","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.mayocp.2016.09.010_bib137","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1182\/blood.V126.23.681.681","article-title":"Durable remissions in children with relapsed\/refractory ALL treated with T cells engineered with a CD19-targeted chimeric antigen receptor (CTL019)","volume":"126","author":"Grupp","year":"2015","journal-title":"Blood"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619616305845?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619616305845?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,27]],"date-time":"2020-09-27T02:09:07Z","timestamp":1601172547000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619616305845"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":137,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["S0025619616305845"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2016.09.010","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adult Acute Lymphoblastic Leukemia","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2016.09.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Mayo Foundation for Medical Education and Research","name":"copyright","label":"Copyright"}]}}